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ABSTRACT 
Acclimatization to altitude can improve endurance performance above levels achieved solely by training 
at sea level. There is natural limitation in the applicability of employing terrestrial altitude training – 
namely proximity. A simple, non-cumbersome method of simulating altitude is desirable to many types of 
endurance athletes. The Alto2Lab (Pharma Pacific Inc.), consisting of primarily a breathing tube and silo 
stack, has shown some potential in this role. There is a lack of evidence regarding whether simulated 
altitude exposure triggers abnormal cardiovascular responses. The aim of this study was to provide initial 
evidence of cardiac changes associated with usage patterns that follow distributor guidelines. Twenty-five 
participants (mean age 29 ± 10.7; 16 males; 9 females) volunteered for the study. Subjects underwent a 
baseline ECG recording followed by ECG recording during sham (4-5 mins), hypoxia (~6 mins), and 
recovery (3-4 mins) phases. The sham phase consisted of subjects breathing normoxive air through a foam-
filled silo system. The sham stack mimicked the look and feel of the silo system used to produce hypoxia 
with the difference being a single, soda lime-filled silo. A recovery phase followed hypoxia. Pulse 
oximetry (SpO2) was used to assess oxygen saturation. Cochran’s Q was employed to test the frequencies 
of responses across the phases. An independent, blinded, experienced clinician (DK) analyzed the 
recordings. Two subjects were removed from the final analysis (inability to finish the protocol, baseline 
right bundle branch block). All subjects demonstrated an increase in heart rate (mean = +16.8 ± 8.0) during 
the hypoxia (mean oxygen saturation = 82 ± 4.1%) phase. No ECG ischemic changes were seen across any 
of the phases. Benign conduction abnormalities (sinus arrhythmia = 9; junctional rhythms = 4) occurred 
with some regularity during hypoxia. These abnormalities occurred with less frequency during the sham 
and recovery phases. It is possible that an altered breathing pattern or an inadequate washout period 
between phases might account for these findings. Overall, there was no significant relationship between 
the heart response and phase (p = .375). While the Alto2Lab did not produce any ECG changes indicative 
of an ischemic response, the present study used a small sample of healthy, recreationally-active 
participants. A larger study employing patients among higher risk categories would provide data that is 
not currently present in the literature and to which this trial cannot speak. 
 
